Cole joins investment arm of CVS Health. Oct 9, 2026 - Oishani Mitra. Bryna Cole spent nearly five years at The Blue Venture Fund before moving to join CVS Health Ventures as an investor. Bryna Cole has left her role as associate at The Blue Venture Fund (BVF) and Sandbox Industries to join CVS Health Ventures as an investor. At CVS Health Ventures, the investment arm of healthcare company CVS Health, Cole will be part of the growth equity team where she will seek out later-stage, high-impact companies that provide strategic value to the business that CVS Health can support with growth capital. Cole spent nearly five years at BVF, a unique collaboration between the Blue Cross Blue Shield Association, Sandbox Industries and over 36 independent Blue Cross Blue Shield (BCBS) companies and their affiliates, in various roles. Prior to that, Cole held investment and business management roles at global private markets firm Partners Group, where she focused on ESG and impact investing and corporate strategy and development. With $1.5bn under management across five funds and a clinical fund, BVF invests in promising emerging companies of strategic relevance to BCBS companies and provides its portfolio with access to BCBS companies to deploy innovation at scale. Launched in 2021, CVS Health Ventures invests in and partners with companies with the potential for technology-enabled innovation and disruption in digital healthcare. The unit prefers to invest in the tech-enabled workflow, technology and healthcare sectors. See all the recent deals by CVS Health Ventures in the CVC Funding Round Database. Oishani Mitra. Oishani Mitra is the content manager for Global Corporate Venturing. Unlock GCV membership. GCV membership connects your team with leading corporate investors, trusted data and a global network to support smarter strategic decisions.

Big Health raises $23.7M in new funding. February 12, 2026 Big Health, a San Francisco, CA-based developer of digital treatments for mental health conditions, raised $23.7M in new funding. The round was led by .406 Ventures and AlleyCorp, with participation from CVS Health Ventures, Blue Venture Fund, Sandbox Clinical Ventures, Gilde Healthcare, and Supermoon Capital. The company intends to sue the funds to accelerate access to its FDA-cleared, reimbursable solutions. Led by CEO Yael Berman, Big Health is a digital mental health treatments company that expand access to care, including behavioral medicine by making treatments available both directly to patients and through providers, and by improving adoption for providers, payers, and employers. Its FDA-cleared, reimbursable solutions include SleepioRx for insomnia disorder and DaylightRx for generalized anxiety disorder (GAD). To date, Big Health has supported more than 750,000 individuals, with clinical studies showing that up to 76% of SleepioRx patients achieve improvement in insomnia, and 71% of DaylightRx patients experience improvement in GAD. 12/02/2026